Core Insights - Royal Philips published its Annual Report 2025, which will be discussed at the Annual General Meeting of Shareholders on May 8, 2026 [1] - The report has been filed with the Netherlands Authority for the Financial Markets in European Single Electronic Format and is expected to be filed with the U.S. Securities and Exchange Commission [2] - The Annual Report 2025 is accessible to shareholders and interested parties online, with printed copies available upon request [3] Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation [4] - The company specializes in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and personal health solutions, employing approximately 64,800 people and generating sales of EUR 18 billion in 2025 [5]

Group 1 - Royal Philips intends to extend the settlement of two forward contracts for 2 million long-term incentive plan shares each, postponing the maturity dates from Q4 2025 to Q4 2026 as part of its share repurchase program announced on June 14, 2023 [1] - Philips generated sales of EUR 18 billion in 2024 and employs approximately 67,300 employees, with operations in over 100 countries [3] - The company focuses on health technology, emphasizing patient- and people-centric innovation to improve health and well-being through advanced technology and clinical insights [2][3] Group 2 - Philips is a leader in various sectors including diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics, and personal health [3] - The company’s share repurchase program is part of its broader strategy to enhance shareholder value [1]